MELBOURNE, AUSTRALIA--(Marketwire - Oct 8, 2012) - Prana Biotechnology Limited ( NASDAQ : PRAN ) ( ASX : PBT ) today announced that it has identified the below correction to a table lodged in the Company's Annual Report on 28 September 2012.The table appears on page 45 on the notes to the financial statements in the annual report.The correction related to 2012 "Short-term employee benefits" and "Post-employment benefits." The revised table is attached.

Finalisation of printing of the annual report is now underway and Prana looks forward to the report being dispatched to all shareholders who have nominated to receive a hard copy of the report in the near future.The revised report will also be released on the ASX at that same time.

About Prana Biotechnology Limited Prana Biotechnology was established to commercialize research into age-related neurodegenerative disorders. The Company was incorporated in 1997 and listed on the Australian Securities Exchange in March 2000 and listed on NASDAQ in September 2002.Researchers at prominent international institutions including The University of Melbourne, The Mental Health Research Institute (Melbourne) and Massachusetts General Hospital, a teaching hospital of Harvard Medical School, contributed to the discovery of Prana's technology.

For further information please visit the Company's web site at http://www.pranabio.com.

See the rest here:
Prana Biotechnology: Revised Table in 2012 Annual Report

Mumbai, Oct 7:

The Association of Biotechnology Led Enterprises (ABLE), the apex body of the biotechnology sector in India, and the US-based Washington Biotechnology and Biomedical Association (WBBA) have signed a memorandum of understanding (MoU) to enable broad ranging co-operation in the field of biotechnology. The duo will support breakthrough discoveries in healthcare, agriculture and clean energy in the country.

Both ABLE and WBBA are to provide each others members an opportunity to co-operate and invest in the State of Washington and in India, in the field of biotechnology. These activities could be current ones that both associations are engaged in, or future ones that both may decide to do individually or jointly.

Activities could concern technical knowledge, market research, inputs for policy making, internships, exhibitions, workshops, seminars, capacity building, collaborations, investment and business partnering.

P. M. Murali, President, ABLE said, The collaboration aims to achieve breakthrough discoveries to provide affordable solutions for critical diseases, important challenges in agriculture and energy on mutually agreed topics.'

Chris Rivera, President, WBBA said, We see India as the growth engine of tomorrow and one of the fastest growing economies in the world. The collaboration with ABLE is significant to facilitate best of research in biotechnology from both the countries.

Link:
Biotech bodies in investment tie-up

WASHINGTON--(BUSINESS WIRE)--

The Biotechnology Industry Organization (BIO) announces plenary sessions for the BIO Investor Forum, an international biotech investor conference focused on investment strategies for early stage and established private companies as well as emerging public companies. Hosted by BIO, the 11th annual event will take place at the Palace Hotel on October 9-10 in San Francisco, Calif.

Our plenary sessions feature an esteemed group of industry analysts and investors that speak to the pressing business issues directly affecting investment in biotech, said Alan Eisenberg, executive vice president, Emerging Companies & Business Developmentat BIO. Attendees have come to expect stimulating dialogue which will offer insight and guidance on how to best approach the challenges facing the industry.

Plenary Sessions include:

Opening Plenary Session It Takes a Village: The New Pharma-VC Model for Biotech Investing Tuesday, October 9, 12:00 p.m. 1:35 p.m. High-profile funding collaborations between pharmaceutical companies and traditional venture capital funds have made headlines in recent months, pooling resources and expertise in an attempt to source and develop the most successful drugs. This panel will examine what factors are driving this new model of biotech investing from both the VC and pharma standpoints and how these deals are structured. Moderator: Alan F. Eisenberg, EVP, Emerging Companies & Business Development, Biotechnology Industry Organization (BIO) Panelists: Francesco De Rubertis, Partner, Index Ventures; Jonathan MacQuitty, PhD, Partner, Abingworth, LPand Brian McVeigh, CPA, CMA, CLP, MBA, Vice President, WWBD Transactions & Investment Management, GlaxoSmithKline Pharmaceuticals

Lunch Plenary Session Tried & True or Something New? Dissecting the New Corporate VC Model Wednesday, October 10, 12:30 p.m. 1:25 p.m. Funded by deep pharma pockets and an investment strategy often focused on early stage, corporate venture capital (CVC) has been a much-needed funding source for companies struggling to keep their development programs moving. The CVC model has been around since the early 1970s, but a new crop of CVCs has sprouted in recent years. A panel of leading CVCs will explore how the CVC model has changed over time and whether these changes measure up to the tried and true models. Moderator: Joseph S. Dillon, CLP, Managing Director, Investor Relations & Business Development, Biotechnology Industry Organization (BIO) Panelists: Jeff Calcagno, MD, Senior Director, Emerging Technologies, California Innovation Center, Johnson & Johnson: Lauren Silverman, PhD, Managing Director, Novartis Option Fund; Ron Laufer, MD, MPH, Senior Managing Director, MedImmune Ventures and Geeta Vemuri, PhD, Senior Managing Director, Baxter Ventures

Closing Plenary Session Forecasting 2013: Trick or Treat? Wednesday, October 10, 4:00 p.m. 5:00 p.m. Seasoned biotech investors engage in a candid and insightful discussion on what the industry can expect in 2013. Topics to be covered include: IPO markets; big pharma acquisitions and their effect on the biotech pipeline and early-stage funding sources. Moderator: Joel Sendek, Managing Director, Head Healthcare Equity Research, Stifel Nicolaus Panelists: Srini Akkaraju, PhD, MD, Managing Director, New Leaf Venture Partners; Evan McColloch, Portfolio Manager, Franklin Templeton Investments; Bryan Roberts, PhD, Partner, Venrock and Asish Xavier, PhD, Vice President, Johnson & Johnson Development Corporation

In addition to Plenary Sessions, the Investor Forum will feature Business Roundtables which will take a closer look at both early stage financing and late stage exit strategies for private companies.

Business Roundtables include:

The New Kids on the Biotech Block: Trends in Early Stage Financing Tuesday, October 9th, 9:00 a.m. 9:55 a.m. Although venture capital financing continues to decrease in the life sciences, the dearth in capital has spawned a new team of funders that are stepping up to the plate to fill the gap. Panelists will discuss what unique experiences these new players bring and how they will impact and improve the drug development process. Moderator: Jeron Eaves, Senior Practice Executive, Campbell Alliance Panelists: Lindy Fishburne, Executive Director, Breakout Labs, Thiel Foundation; Mark Goldsmith, MD, PhD, Venture Partners, Third Rock Ventures; Walter C. Ogier, President & CEO, Acetylon Pharmaceuticals, Inc and Robert Sarisky, PhD, Chief Business Officer, Forma Therapeutics, Inc.

See the original post:
BIO Announces Plenary Sessions for 11th Annual BIO Investor Forum

By Brian D. Pacampara | More Articles October 3, 2012 |

Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, the iShares Nasdaq Biotechnology Index (Nasdaq: IBB) has earned a respected four-star ranking.

With that in mind, let's take a closer look at IBB and see what CAPS investors are saying about the ETF right now.

iShares Nasdaq Biotechnology facts

Sources: Morningstar and Motley Fool CAPS.

On CAPS, 93% of the 177 members who have rated iShares Nasdaq Biotechnology believe the ETF will outperform the S&P 500 going forward.

Earlier this year, one of those Fools, ravens9111, tapped iShares Nasdaq Biotechnology as a particularly smart way to get into the space: "Playing individual biotech stocks is risky business. This is probably the least risky way to play the sector without taking a chance of waking up one morning to see the company's drug was rejected and opens down 50%+ on an FDA rejection."

Owning exceptional ETFs is a surefire way to secure your financial future. Of course, despite a strong four-star rating, iShares Nasdaq Biotechnology may not be your top choice.

If that's the case, our special report on ETFs highlights three funds that are poised to soar in the next recovery. It's 100% free, but won't last forever, so click here to access it now.

Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.

The rest is here:
4-Star ETFs Poised to Pop: iShares Nasdaq Biotechnology

NEW YORK, NY--(Marketwire - Oct 4, 2012) - The Biotechnology Industry has seen increased investor interest in 2012 as it continues to impress with strong gains. The iShares NASDAQ Biotechnology Index ETF (IBB) has gained over 35 percent this year, more than double the S&P 500 Index's gain of 15 percent. New legislation, increased mergers & acquisition activity as a result of major patent expirations have all been contributing factors to industry's rapid rise in 2012. Five Star Equities examines the outlook for companies in the Biotech Industry and provides equity research on AspenBio Pharma, Inc. ( NASDAQ : APPY ) and Keryx Biopharmaceuticals ( NASDAQ : KERX ).

Access to the full company reports can be found at:

http://www.FiveStarEquities.com/APPY

http://www.FiveStarEquities.com/KERX

The Biotechnology Industry Organization (BIO) has recently praised the introduction of the High Technology Small Business Research Incentives Act. The new legislation would allow investors of joint venture R&D projects to utilize the losses and tax credits.

"Through the tax code, Congress historically has provided opportunities that encourage private investment in pre-revenue, R&D-intensive companies. The early growth of the biotech industry in the 1980s was due in part to the ability of investors to support projects aimed at finding new cures and treatments through similar joint ventures. This legislation will help spur greater private investment in biotech and other R&D intensive industries," BIO's President and CEO Jim Greenwood said in a statement.

Five Star Equities releases regular market updates on the Biotech Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at http://www.FiveStarEquities.com and get exclusive access to our numerous stock reports and industry newsletters.

AspenBio Pharma is an in vitro diagnostic company focused on the clinical development and commercialization of its blood-based appendicitis test. The company plans to initiate a pivotal study in the fourth quarter of 2012 for its blood-based appendicitis test.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease. Keryx is developing Zerenex, an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes.

Five Star Equities provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. Five Star Equities has not been compensated by any of the above-mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at: http://www.FiveStarEquities.com/disclaimer

Read the original:
Biotech Industry Look to Benefit From New Act Designed to Promote R&D Joint Ventures

CAMBRIDGE, Mass.--(BUSINESS WIRE)--

Lando and Anastasi, LLP (L&A) today announced that William Seymour, Ian Mullet, Mark Nickas, Jessica Colantonio, and Kenneth Thompson have joined the firm.

The Cambridge-based intellectual property law firm, one of the largest IP firms in New England, has continued its rapid growth. The L&A litigation, chemical and materials, biotechnology and pharmaceutical, and electrical and computer science practice areas are expanding to support strong business growth in 2012. The firms commitment to high quality counsel, responsive service, and value make it sought after by large companies and start-ups alike.

William Seymour is an Associate at L&A. He will focus his practice on patent and trademark litigation and counseling. Prior to joining L&A, he was an Associate at Stroock & Stroock & Lavan, LLP in New York. Bill is registered to practice before the United States Patent and Trademark Office, and is a member of the New York Bar.

Bill graduated from Boston University School of Law, where he was the Note Editor of the Journal of Science and Technology Law. He received a B.S. in Civil/Environmental Engineering and a B.A. in Political Science from Northeastern University.

We are excited that Bill has joined us, commented Craig Smith, a Litigation Partner at L&A. He brings just the right skills to complete our litigation team, and we are very pleased to be able to immediately integrate him into several or our ongoing matters.

Ian Mullet is an Associate at L&A, and focuses his practice on patent prosecution in the areas of chemical and materials science, as well as in counseling and litigation support in a variety of technologies. He was previously a Summer Associate at L&A.

Ian graduated from the University of New Hampshire School of Law, where he was the Associate Editor of IDEA: the Intellectual Property Law Review. He received an M.S. in Chemical Engineering from the University of Texas, and a B.A. in Liberal Arts from Saint Johns College.

Peter Lando, the senior member of the Chemical and Materials Science Group, noted, We have been looking forward to welcoming Ian back to the firm since his summer associateship last year. He proved himself to be a motivated and insightful member of our team, and we are thrilled that he has joined us full-time this fall.

Mark Nickas is an Associate at L&A, and focuses his practice on patent prosecution, diligence and counseling in the biomedical and biotechnology fields, including microbiology, immunology, biochemistry, and molecular and cell biology. He was previously a Summer Associate at L&A, and is registered to practice before the United States Patent and Trademark Office.

See the original post here:
Lando & Anastasi, LLP Expands Litigation, Chemical/Materials, Biotechnology/Pharmaceutical, and Electrical/Computer ...

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/ddm5g7/royalty_rates_for) has announced the addition of the "Royalty Rates for Pharmaceuticals & Biotechnology, 8th Edition" report to their offering.

Royalty Rates for Pharmaceuticals & Biotechnology features more real-deal royalty rates, license fees, and milestone payment benchmarks than any other publication.

The eighth edition of Royalty Rates for Pharmaceuticals & Biotechnology contains hundreds of royalty rates and other financial compensation benchmarks that can be used to optimize the pricing of biotechnology and pharmaceutical innovations. You'll find updated and expanded information from past editions as well as an increased number of reported license agreements. This new edition and the transaction details have been collected from well-established sources over a period of 22 years of research.

Royalty Rates for Pharmaceuticals & Biotechnology provides real-deal information for hundreds of transactions, including the technology licensed, royalty rates, license fees, and milestone payments. And it goes well beyond the rates to provide context for each deal analyzed. This unique resource is organized into two useful sections:

The first section covers the theory associated with deriving royalty rates. An overview of intellectual property value is included along with seven methods that can be employed to derive royalty rates: Simple Rules of Thumb, Industry Guidelines, Discounted Cash Flow Analysis, Risk-Adjusted Net Present Value Analysis, Infringement Damages Analysis, Comparable License Transactions, Investment Rate of Return Analysis, and the Relief-From-Royalty Method.

The second section of this one-of-a-kind report presents detailed financial information from real-world transactions. You'll find information on the parties involved in the transactions along with a description of the technology exchanged and all financial details that could be discovered.

For more information visit http://www.researchandmarkets.com/research/ddm5g7/royalty_rates_for

See the article here:
Research and Markets: Royalty Rates for Pharmaceuticals & Biotechnology, 8th Edition

WASHINGTON--(BUSINESS WIRE)--

The Biotechnology Industry Organizations (BIO) 2012 Pacific Rim Summit on Industrial Biotechnology and Bioenergy will feature breakout sessions focused on using biomass to replace fossil fuels in creating bioenergy, biofuels and other bioproducts. The Summit takes place October 9-12 at the Westin Bayshore in Vancouver, Canada. Online registration is available.

Biomass has great potential to provide renewable energy for the future, said Brent Erickson, executive vice president for BIOs Industrial & Environmental Section. Vancouver is an ideal location for this discussion as Canadas forests represent an immensely abundant source of forest biomass. Biomass fuels and products are a way to reduce the need for oil and gas imports; to support the growth of agriculture, forestry, and rural economies; and to foster major new domestic industries biorefineries making a variety of fuels, chemicals, and other products.

BIOs Pacific Rim Summit featured breakout sessions include:

Forestry Companies Discovering the Biorefinery Within Wednesday, October 10, 8:30-10am

Creating an Acceptable Supply of Biomass Feedstock to Satisfy Project Financing Requirements Wednesday, October 10, 8:30-10am

Next-Gen Feedstocks: Grass, Reeds, and Macroalgae Wednesday, October 10, 10:30am-12pm

The Challenge of Sustainable Feedstock: Certification and Reputation Management for Producers and Brand Owners Wednesday, October 10, 2:30-4pm

Media registration is now open and available. Complimentary media registration is available to editors and reporters with valid press credentials working full time for print, broadcast or web publications.

Now in its seventh year, the Pacific Rim Summit on Industrial Biotechnology and Bioenergy will address the latest issues in industrial biotechnology, including algae, advanced biofuels, biopolymers and bioplastics, dedicated energy crops, green chemistry, and synthetic biology. The annual Pacific Rim Summit is the original conference dedicated solely to growth of the industrial biotechnology sector in Asia and the Americas. Visit http://bio.org/pacrim.

Read more:
BIO Pacific Rim Summit to Showcase Role of Biomass in Building Biobased Economy

By Robert Weisman, Globe Staff

The states largest biotechnology trade group sent a letter to Cambridge city officials Monday opposing a proposal by neighborhood activists that would change zoning in an area around Central Square, which would potentially block large-scale development or expansion plans for life sciences companies.

In the letter to the chairmen of the Cambridge City Councils ordinance committee and the Cambridge Planning Board, Robert K. Coughlin, president of the Cambridge-based Massachusetts Biotechnology Council, noted that the city is home to more than 110 life sciences companies that are drawn to nearby research universities and hospitals.

The life sciences industry has always sought to be a good neighbor and active corporate citizen in the life of Cambridge, Coughlin wrote. With this commitment in mind, we encourage you to defeat the downzoning proposal. We feel that it would restrict the kind of sustainable development that brings tremendous benefits to the people of Cambridge.

Read more:
Massachusetts Biotechnology Council says Central Square zoning proposal would hurt life sciences

NEWARK, Del.--(BUSINESS WIRE)--

SDIX (SDIX), a leading provider of biotechnology-based products and services, today announced it has entered into an agreement to sell the assets of its Food Safety and GMO businesses to Romer Labs for $13.5 million. Following this transaction, the Company will concentrate on its Life Science business. Romer Labs is acquiring the intellectual property, current inventory and commercial contracts, as well as the equipment for the two businesses and will employ the current staff.

Francis DiNuzzo, SDIXs President and CEO, commented, The sale of our Food Safety and GMO businesses to Romer Labs, represents a continued commitment to focus on our core Life Science business, and our Advanced GAT technologies. We continue to make important progress as we work to develop our Advanced GAT technology which is targeted at the discovery of monoclonal antibodies to be used in high value applications such as biotherapeutics and biomarker discovery. The net cash from this sale will strengthen our balance sheet and provide additional investment flexibility for our Life Science businesses.

The acquisition is expected to be completed during the fourth quarter of 2012.

Mr. DiNuzzo went on to say We are pleased to not only achieve great value for SDIX shareholders, but also to place our Food Safety and GMO assets in good hands with Romer Labs. I would like to thank all our employees and customers as we wish Romer Labs continued success with the RapidChek product line and GMO business.

About SDIX (www.sdix.com)

SDIX is a biotechnology company with a core expertise in creating better antigens, better antibodies and better assays for the pharmaceutical and biotechnology markets. For over 20 years, SDIX has been a leading immuno-solutions company, developing results-oriented and innovative antibody-based solutions that enable customers to meet high performance research, diagnostic and commercialization objectives. In the life science market, SDIXs technology and capabilities are being used to help discover disease mechanisms, facilitate development of new drugs and provide antibodies and assays for the diagnosis of disease.

About Romer Labs

Romer Labs, founded in Washington, MO, in 1982, is a leader in diagnostic solutions for food and feed safety. It develops, manufactures and markets test kits for food allergens, mycotoxins, veterinary drug residues and other food contaminants. The company also operates four accredited full-service laboratories on three continents. Romer Labs has facilities in Austria, Brazil, China, Malaysia, Singapore, UK and the USA. For more than 30 years, Romer Labs has been a trusted partner for the food and feed industry worldwide.

This news release may contain forward-looking statements reflecting SDIX's current expectations. When used in this press release, words like anticipate, could, enable, estimate, intend, expect, believe, can, potential, will, should, project, plan and similar expressions as they relate to SDIX are intended to identify said forward-looking statements. Investors are cautioned that all forward-looking statements involve risks and uncertainties, which may cause actual results to differ from those anticipated by SDIX at this time. Such risks and uncertainties include, without limitation, changes in demand for products, the application of our technologies to various uses, delays in product development, delays in market acceptance of new products, retention of customers and employees, adequate supply of raw materials, inability to obtain or delays in obtaining fourth party, or required government approvals, the ability to meet increased market demand, competition, protection of intellectual property, non-infringement of intellectual property, seasonality, and other factors more fully described in SDIX's public filings with the U.S. Securities and Exchange Commission.

Original post:
SDIX Sells Food Safety and GMO Businesses to Romer Labs for $13.5 Million

WASHINGTON--(BUSINESS WIRE)--

Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO John J. Castellani and Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood today released the following joint statement on the implementation of the Prescription Drug User Fee Act (PDUFA V):

Today, as implementation of PDUFA V officially commences, PhRMA and BIO stand together to usher in an exciting new era in regulatory science a period that holds great promise for bringing new, innovative medicines to patients in a timely manner.

A reliable, science-driven regulatory environment fosters innovation, promotes economic competitiveness and helps maintain high patient confidence in the integrity of our medicines. PDUFA V, reauthorized in July 2012 as part of the Food and Drug Administration Safety and Innovation Act (FDASIA), is a significant step in this direction.

If implemented successfully, PDUFA V will refocus the program on its original intent timely patient access to new medicines while strengthening FDAs high safety standards and helping to establish a new system-wide approach to regulatory science that embraces the scientific tools used in 21st century drug development.

Among its many forward-looking provisions, PDUFA V will enable more timely patient access to safe and effective new medicines through enhanced scientific communications with sponsors during drug development and throughout the drug review process. It also will support the development of a framework to facilitate benefit/risk evaluations of new medicines and integrate patient perspectives in the review process, with a particular focus on diseases with considerable unmet needs.

Under PDUFA V, FDA will have increased resources and staffing to validate the use of new scientific tools, such as pharmacogenomics and biomarkers, that can help demonstrate therapeutic benefits more rapidly. The Agency also will have dedicated resources to evaluate the use of meta-analyses and provide guidance on standardized methodologies for their use in drug review and safety monitoring.

In addition, FDA will have the resources to further strengthen its already robust focus on patient safety by standardizing risk evaluation and mitigation strategies (REMS) and helping to make them less burdensome to implement for the healthcare community.

PDUFA V reflects unprecedented collaboration and transparency among healthcare stakeholders, including PhRMA, BIO, FDA and, importantly, the patients we serve. It also reflects strong bipartisan efforts within Congress to reauthorize the program in a timely manner.

Unlike prior PDUFA agreements, the architecture of PDUFA V provides opportunities for continuous engagement and assessment for all stakeholders that will allow us to build toward the next reauthorization in 2017. It is incumbent upon us to help ensure that PDUFA V lives up to its vast potential.

Read more:
PDUFA V Sets New Course for Regulatory Science – Joint BIO/PhRMA Statement

NEW YORK, NY--(Marketwire - Oct 1, 2012) - The Biotechnology Industry has seen increased investor interest in 2012 as it continues to impress with strong gains. The iShares NASDAQ Biotechnology Index ETF (IBB) has gained over 35 percent this year, more than double the S&P 500 Index's gain of 15 percent. New legislation, increased mergers & acquisition activity as a result of major patent expirations have all been contributing factors to industry's rapid rise in 2012. Five Star Equities examines the outlook for companies in the Biotech Industry and provides equity research on Biosante Pharmaceuticals Inc. ( NASDAQ : BPAX ) and Neostem Inc. ( NYSE : NBS ).

Access to the full company reports can be found at: http://www.FiveStarEquities.com/BPAX http://www.FiveStarEquities.com/NBS

The Biotechnology Industry Organization (BIO) has recently praised the introduction of the High Technology Small Business Research Incentives Act. The new legislation would allow investors of joint venture R&D projects to utilize the losses and tax credits.

"Through the tax code, Congress historically has provided opportunities that encourage private investment in pre-revenue, R&D-intensive companies. The early growth of the biotech industry in the 1980s was due in part to the ability of investors to support projects aimed at finding new cures and treatments through similar joint ventures. This legislation will help spur greater private investment in biotech and other R&D intensive industries." BIO's President and CEO Jim Greenwood said in a statement.

Five Star Equities releases regular market updates on the Biotech Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at http://www.FiveStarEquities.com and get exclusive access to our numerous stock reports and industry newsletters.

BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. The company has announced that the independent Data Monitoring Committee (DMC) has completed the ninth unblinded review of the LibiGel Phase III cardiovascular events and breast cancer safety study.

NeoStem recently announced a significant expansion in its claims granted to protect the use of CD34+ cells. "We received notification that claims granted in the United States have now been granted by the Japanese Patent Office. Additionally, we received recently a Notice of Allowance from the U.S. Patent Office that further expands the scope and protection of our existing CD34+ product patents here in the U.S.," said Andrew Pecora, M.D. FACP CPE, Chief Medical Officer of NeoStem.

Five Star Equities provides Market Research focused on equities hat offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. Five Star Equities has not been compensated by any of the above-mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at: http://www.FiveStarEquities.com/disclaimer

Follow this link:
Biotech Industry Looks to Benefit From New Act Designed to Promote R&D Joint Ventures

MELBOURNE, AUSTRALIA--(Marketwire - Oct 1, 2012) - Prana Biotechnology Limited ( NASDAQ : PRAN ) ( ASX : PBT ) today announced that it has raised A$6.0 million (approx.) through a placement of 32,500,000 ordinary fully paid shares (equivalent to 3.25 millionNASDAQ listed ADRs) at a price of A$0.185 per share. The placement attracted strong demand even though the amount raised was restricted by the number of shares which could be issued by the Company under ASX listing rule 7.1, thereby not requiring a separate meeting of shareholders.

The placement was subscribed by a range of leading Australian institutional investors within the healthcare sector in Australia, as well as several High Net Worth Investors. The placement was managed by JM Financial Group Limited, based in Melbourne.

The capital was raised in order to support Prana's two ongoing Phase 2 clinical trials, the IMAGINE trial and Reach2HD trial, testing the effects of its lead drug candidate, PBT2, in Alzheimer's and Huntington disease patients, respectively. Results are anticipated to be reported in 2H13.

"The funds raised by Prana via this placement, reflect strong commitment to Prana's clinical development programmes and the commercial opportunity this provides. The endorsement of and participation by some of Australia's leading healthcare investors is very welcome," said Geoffrey Kempler, Prana's Executive Chairman.

Prana management and scientific advisors are on a roadshow this week in Melbourne, New York, Boston and London, updating the investment community on Prana's progress.

About Prana Biotechnology Limited Prana Biotechnology was established to commercialize research into age-related neurodegenerative disorders. The Company was incorporated in 1997 and listed on the Australian Securities Exchange in March 2000 and listed on NASDAQ in September 2002.Researchers at prominent international institutions including The University of Melbourne, The Mental Health Research Institute (Melbourne) and Massachusetts General Hospital, a teaching hospital of Harvard Medical School, contributed to the discovery of Prana's technology.

For further information please visit the Company's web site at http://www.pranabio.com.

Forward Looking Statements This press release contains "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934.The Company has tried to identify such forward-looking statements by use of such words as "expects," "intends," "hopes," "anticipates," "believes," "could," "may," "evidences" and "estimates," and other similar expressions, but these words are not the exclusive means of identifying such statements.Such statements include, but are not limited to any statements relating to the Company's drug development program, including, but not limited to the initiation, progress and outcomes of clinical trials of the Company's drug development program, including, but not limited to, PBT2, and any other statements that are not historical facts.Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to the difficulties or delays in financing, development, testing, regulatory approval, production and marketing of the Company's drug components, including, but not limited to, PBT2, the ability of the Company to procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company's drug compounds, including, but not limited to, PBT2, that could slow or prevent products coming to market, the uncertainty of patent protection for the Company's intellectual property or trade secrets, including, but not limited to, the intellectual property relating to PBT2, and otherrisks detailed from time to time in the filings the Company makes with Securities and Exchange Commission including its annual reports on Form 20-F and its reports on Form 6-K.Such statements are based on management's current expectations, but actual results may differ materially due to various factions including those risks and uncertainties mentioned or referred to in this press release.Accordingly, you should not rely on those forward-looking statements as a prediction of actual future results.

See original here:
Prana Announces A$6.0 Million Capital Raising

SAN DIEGO--(BUSINESS WIRE)--

Medistem Inc (Pink Sheets:MEDS) announced today the initiation of a collaboration with Superview Biotechnology Co. Ltd, a subsidiary of Yinhuan Holding Co from Yixing, China. The joint work will be aimed at using proprietary stem cell lines developed by Medistem for screening of monoclonal antibodies for therapeutic activity in the area of regenerative medicine. As part of the collaboration, the two companies will evaluate various candidates jointly, as well as apply for grants and share research data.

To date, the majority of stem cell companies are focusing on the stem cell itself being a product. By collaborating with Superview Biotechnology, we aim to assess the feasibility of developing antibodies that can modulate the activity of stem cells that already exist in the body, said Thomas Ichim, CEO of Medistem. This approach not only provides methods of activating stem cells but also allows for the development of stem cell adjuvant therapies that could be used to resurrect stem cell candidates that failed in clinical trials.

Superview Biotechnology has developed proprietary methods of rapidly generating monoclonal antibodies to esoteric protein targets. Medistem has a history of success in the area of stem cells, being the only company to take a stem cell product from discovery to FDA clearance in the short span of 4 years.

One of the significant driving forces behind our company is to develop innovative targets for our monoclonal antibodies. Although monoclonal antibodies have generated sales of billions of dollars in areas ranging from rheumatoid arthritis, to cancer, to preventing blindness, we feel that the potential of this therapeutic tool is only beginning to be recognized, said Jiong Wu, CEO of Superview Biotechnology. Our opinion is that the barriers to entry for monoclonal antibody-based therapies modulating endogenous stem cells is lower than stem cell based therapies. We are eager to work with the Medistem team at exploring this hypothesis.

A joint grant is expected to be filed with the National Natural Science Foundation of China to support part of the proposed collaboration by end of October, 2012.

Cautionary Statement

This press release does not constitute an offer to sell or a solicitation of an offer to buy any of our securities. This press release may contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking information. Factors which may cause actual results to differ from our forward-looking statements are discussed in our Form 10-K for the year ended December 31, 2007 as filed with the Securities and Exchange Commission.

The rest is here:
Medistem and Superview Biotechnology Co. Ltd. Initiate Collaboration on Therapeutics Development Using Antibody and ...

Background:
The lack of sequenced genomes for oleaginous microalgae limits our understanding of themechanisms these organisms utilize to become enriched in triglycerides. Here we report thede novo transcriptome assembly and quantitative gene expression analysis of the oleaginousmicroalga Neochloris oleoabundans, with a focus on the complex interaction of pathwaysassociated with the production of the triacylglycerol (TAG) biofuel precursor.
Results:
After growth under nitrogen replete and nitrogen limiting conditions, we quantified thecellular content of major biomolecules including total lipids, triacylglycerides, starch, protein,and chlorophyll. Transcribed genes were sequenced, the transcriptome was assembled denovo, and the expression of major functional categories, relevant pathways, and importantgenes was quantified through the mapping of reads to the transcriptome. Over 87 million, 77base pair high quality reads were produced on the Illumina HiSeq sequencing platform.Metabolite measurements supported by genes and pathway expression results indicated thatunder the nitrogen-limiting condition, carbon is partitioned toward triglyceride production,which increased fivefold over the nitrogen-replete control. In addition to the observedoverexpression of the fatty acid synthesis pathway, TAG production during nitrogenlimitation was bolstered by repression of the beta-oxidation pathway, up-regulation of genesencoding for the pyruvate dehydrogenase complex which funnels acetyl-CoA to lipidbiosynthesis, activation of the pentose phosphate pathway to supply reducing equivalents toinorganic nitrogen assimilation and fatty acid biosynthesis, and the up-regulation of lipases--presumably to reconstruct cell membranes in order to supply additional fatty acids for TAGbiosynthesis.
Conclusions:
Our quantitative transcriptome study reveals a broad overview of how nitrogen stress resultsin excess TAG production in N. oleoabundans, and provides a variety of genetic engineeringtargets and strategies for focused efforts to improve the production rate and cellular contentof biofuel precursors in oleaginous microalgae.Source:
http://www.biotechnologyforbiofuels.com/rss/

MELBOURNE, AUSTRALIA--(Marketwire - Sep 28, 2012) - Prana Biotechnology ( NASDAQ : PRAN ) ( ASX : PBT ) today announced that Chief Scientific Advisor, Rudy Tanzi, Joseph P. and Rose F. Kennedy, Professor of Neurology, Harvard Medical School, will take part in a webcasthosted by George Zavoico, Ph.D., Managing Director and Senior Analyst, of MLV & Co.The topic of the webcast will be: "Alzheimer's Disease Therapeutics: Recent Setbacks and Emerging Alternatives."The webcast will take place on Monday, October 1, at 2:00 pm Eastern Daylight Time (NYC).

The session will consider what are the most promising new technologies for fighting Alzheimer's Disease which, with all other types of dementia, currently affects more than 36 million people worldwide.Participants will hear about innovative technologies and the best way forward for combating Alzheimer's and other age related diseases.Professor Tanzi will address the potential impact of the recent failures of Pfizer's bapineuzumab and Eli Lilly's solanezumab Phase 3 trials and discuss the possible scientific reasons why they did not succeed.

Investors are invited to participate.To obtain dial-in information please contact: Leslie Goedken at 646-556-9206, lgoedken@mlvco.com;or Scott Ammaturo at 646-556-9218, sammaturo@mlvco.com.

About Prana Biotechnology Limited Prana Biotechnology was established to commercialize research into age-related neurodegenerative disorders. The Company was incorporated in 1997 and listed on the Australian Securities Exchange in March 2000 and listed on NASDAQ in September 2002.Researchers at prominent international institutions including The University of Melbourne, The Mental Health Research Institute (Melbourne) and Massachusetts General Hospital, a teaching hospital of Harvard Medical School, contributed to the discovery of Prana's technology.

For further information please visit the Company's web site at http://www.pranabio.com.

Forward Looking Statements This press release contains "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934.The Company has tried to identify such forward-looking statements by use of such words as "expects," "intends," "hopes," "anticipates," "believes," "could," "may," "evidences" and "estimates," and other similar expressions, but these words are not the exclusive means of identifying such statements.Such statements include, but are not limited to any statements relating to the Company's drug development program, including, but not limited to the initiation, progress and outcomes of clinical trials of the Company's drug development program, including, but not limited to, PBT2, and any other statements that are not historical facts.Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to the difficulties or delays in financing, development, testing, regulatory approval, production and marketing of the Company's drug components, including, but not limited to, PBT2, the ability of the Company to procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company's drug compounds, including, but not limited to, PBT2, that could slow or prevent products coming to market, the uncertainty of patent protection for the Company's intellectual property or trade secrets, including, but not limited to, the intellectual property relating to PBT2, and otherrisks detailed from time to time in the filings the Company makes with Securities and Exchange Commission including its annual reports on Form 20-F and its reports on Form 6-K.Such statements are based on management's current expectations, but actual results may differ materially due to various factions including those risks and uncertainties mentioned or referred to in this press release.Accordingly, you should not rely on those forward-looking statements as a prediction of actual future results.

Go here to read the rest:
Prana Scientist to Participate in Webcast to Discuss Alzheimer's Disease Therapeutics: Recent Setbacks and Emerging ...

NEW YORK, NY--(Marketwire - Sep 28, 2012) - The Biotechnology Industry has seen increased investor interest in 2012 as it continues to impress with strong gains. The iShares NASDAQ Biotechnology Index ETF (IBB) has gained over 35 percent this year, more than double the S&P 500 Index's gain of 15 percent. New legislation, increased mergers & acquisition activity as a result of major patent expirations have all been contributing factors to the industry's rapid rise in 2012. Five Star Equities examines the outlook for companies in the Biotech Industry and provides equity research on AEterna Zentaris Inc. ( NASDAQ : AEZS ) and Cell Therapeutics Inc. ( NASDAQ : CTIC ).

Access to the full company reports can be found at:

http://www.FiveStarEquities.com/AEZS

http://www.FiveStarEquities.com/CTIC

The Biotechnology Industry Organization (BIO) has recently praised the introduction of the High Technology Small Business Research Incentives Act. The new legislation would allow investors of joint venture R&D projects to utilize the losses and tax credits.

"Through the tax code, Congress historically has provided opportunities that encourage private investment in pre-revenue, R&D-intensive companies. The early growth of the biotech industry in the 1980s was due in part to the ability of investors to support projects aimed at finding new cures and treatments through similar joint ventures. This legislation will help spur greater private investment in biotech and other R&D intensive industries," BIO's President and CEO Jim Greenwood said in a statement.

Five Star Equities releases regular market updates on the Biotech Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at http://www.FiveStarEquities.com and get exclusive access to our numerous stock reports and industry newsletters.

Aeterna Zentaris is an oncology and endocrinology drug development company currently investigating treatments for various unmet medical needs. The Company's pipeline encompasses compounds at all stages of development, from drug discovery through to marketed products. The company recently reported that Fast Track designation had not been granted from the FDA for AEZS-130.

Cell Therapeutics is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. The company recently reported positive results from their phase 1 study of its highly selective oral JAK2 inhibitor pacritinib, or SB1518.

Five Star Equities provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. Five Star Equities has not been compensated by any of the above-mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at:

More here:
Biotech Industry Look to Benefit From the Introduction of the High Technology Small Business Research Incentives Act

NEW YORK, NY--(Marketwire - Sep 27, 2012) - The Biotechnology Industry has seen increased investor interest in 2012 as it continues to impress with strong gains. The iShares NASDAQ Biotechnology Index ETF (IBB) has gained over 35 percent this year, more than double the S&P 500 Index's gain of 15 percent. New legislation, increased mergers & acquisition activity as a result of major patent expirations have all been contributing factors to industry's rapid rise in 2012. Five Star Equities examines the outlook for companies in the Biotech Industry and provides equity research on Genetic Technologies Limited ( NASDAQ : GENE ) and MannKind Corporation ( NASDAQ : MNKD ).

Access to the full company reports can be found at:

http://www.FiveStarEquities.com/GENE

http://www.FiveStarEquities.com/MNKD

The Biotechnology Industry Organization (BIO) has recently praised the introduction of the High Technology Small Business Research Incentives Act. The new legislation would allow investors of joint venture R&D projects to utilize the losses and tax credits.

"Through the tax code, Congress historically has provided opportunities that encourage private investment in pre-revenue, R&D-intensive companies. The early growth of the biotech industry in the 1980s was due in part to the ability of investors to support projects aimed at finding new cures and treatments through similar joint ventures. This legislation will help spur greater private investment in biotech and other R&D intensive industries," BIO's President and CEO Jim Greenwood said in a statement.

Five Star Equities releases regular market updates on the Biotech Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at http://www.FiveStarEquities.com and get exclusive access to our numerous stock reports and industry newsletters.

Genetic Technologies is an established diagnostics company with more than 20 years of experience in commercializing genetic testing, noncoding DNA and product patenting. Shares of the company soared after they reported BREVAGen, their breast cancer test, has been cleared for sale into the State of Florida.

MannKind is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. The company's lead investigational product candidate, AFREZZA, is a novel, ultra rapid-acting mealtime insulin therapy.

Five Star Equities provides Market Research focused on equities hat offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. Five Star Equities has not been compensated by any of the above-mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at: http://www.FiveStarEquities.com/disclaimer

Go here to see the original:
Biotech Industry Applauds Introduction of the High Technology Small Business Research Incentives Act

NEW YORK, NY--(Marketwire - Sep 27, 2012) - The Biotechnology Industry has seen increased investor interest in 2012 as it continues to impress with strong gains. The iShares NASDAQ Biotechnology Index ETF (IBB) has gained over 35 percent this year, more than double the S&P 500 Index's gain of 15 percent. New legislation, increased mergers & acquisition activity as a result of major patent expirations have all been contributing factors to industry's rapid rise in 2012. Five Star Equities examines the outlook for companies in the Biotech Industry and provides equity research on Chelsea Therapeutics International Ltd. ( NASDAQ : CHTP ) and Peregrine Pharmaceuticals ( NASDAQ : PPHM ).

Access to the full company reports can be found at:

http://www.FiveStarEquities.com/CHTP

http://www.FiveStarEquities.com/PPHM

The Biotechnology Industry Organization (BIO) has recently praised the introduction of the High Technology Small Business Research Incentives Act. The new legislation would allow investors of joint venture R&D projects to utilize the losses and tax credits.

"Through the tax code, Congress historically has provided opportunities that encourage private investment in pre-revenue, R&D-intensive companies. The early growth of the biotech industry in the 1980s was due in part to the ability of investors to support projects aimed at finding new cures and treatments through similar joint ventures. This legislation will help spur greater private investment in biotech and other R&D intensive industries," BIO's President and CEO Jim Greenwood said in a statement.

Five Star Equities releases regular market updates on the Biotech Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at http://www.FiveStarEquities.com and get exclusive access to our numerous stock reports and industry newsletters.

Chelsea Therapeutics is a biopharmaceutical development company that acquires and develops innovative products for the treatment of a variety of human diseases, including central nervous system disorders. Chelsea is currently pursuing FDA approval in the U.S. for Northera, a novel, late-stage, orally-active therapeutic agent for the treatment of symptomatic neurogenic orthostatic hypotension in patients with primary autonomic failure.

Peregrine Pharmaceuticals is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials focused on the treatment and diagnosis of cancer. The company recently reported that it had found major discrepancies in their phase 2 clinical trial results for its bavituximab. The company is currently conducting a detailed review.

Five Star Equities provides Market Research focused on equities hat offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. Five Star Equities has not been compensated by any of the above-mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at: http://www.FiveStarEquities.com/disclaimer

See more here:
New Legislation and Major Patent Expirations Contributing Factors to Biotech Industry Success in 2012

PORT HUENEME, CA--(Marketwire - Sep 26, 2012) - Stellar Biotechnologies, Inc. ("Stellar") ( TSX VENTURE : KLH ) ( PINKSHEETS : SBOTF ) ( FRANKFURT : RBT ) today announced that Frank Oakes, President and Chief Executive Officer of Stellar, presented at the 2nd Annual World Congress of Marine Biotechnology held September 20 - 23, 2012 in Dalian, China.

"We are the world leader in Keyhole Limpet Hemocyanin (KLH)," said Frank Oakes. "KLH is a critical material in immunology that is derived from a sole marine source, so we are intensely aware of the importance of the ocean's fragile resources to pharmaceutical sciences."

The World Congress of Marine Biotechnology brought together international scientists and industry leaders to discuss the global growth and latest developments in marine biotechnology.Mr. Oakes delivered a keynote talk titled "Marine Compounds in Immune Therapy; the Pathway to Commercialization" focusing on the deployment of KLH in immunology, one of the fastest growing pharmaceutical fields.

Frank Oakes is an international expert in the commercialization of marine-derived products, with specialization in sustainable aquaculture systems for biotechnology and seafood industries.Stellar Biotechnologies is championing KLH protection and development with support from the National Cancer Institute, the National Science Foundation, and the national Center for Research Resources.

For more information: Visit Stellar Biotechnologies website and the KLH knowledge base KLH Site.

About Stellar Biotechnologies, Inc. Stellar Biotechnologies, Inc. ( TSX VENTURE : KLH ) ( PINKSHEETS : SBOTF ) ( FRANKFURT : RBT ) is the world leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH). KLH is an important immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets. Potent, yet proven safe in humans, KLH operates as both a vital component for conjugate vaccines (targeting cancer, autoimmune, and infectious diseases) as well as an antigen for measuring immune status. Stellar Biotechnologies was founded to address the growing demand for renewable, commercial-scale supplies of high-quality, GMP-grade KLH. Stellar has developed leading practices, facilities and proprietary capabilities to address this need. To receive regular updates, enter email at bottom of http://stellarbiotechnologies.com/investors/news_releases/

There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Readers should not place undue reliance on such statements. Except in accordance with applicable securities laws, the Company expressly disclaims any obligation to update any forward-looking statements or forward-looking statements that are incorporated by reference herein. This news release does not constitute an offer to sell, or a solicitation of an offer to buy any of the Company's securities set out herein in the United States, or to, or for the benefit or account of, a U.S. Person or person in the United States. Neither TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of these releases.

Read more:
Stellar Biotechnologies Presented at World Congress of Marine Biotechnology